Dorzolamide/timolol combination versus concomitant administration of brimonidine and timolol: Six-month comparison of efficacy and tolerability
To compare the efficacy and tolerability of the 2% dorzolamide/0.5% timolol combination ophthalmic solution twice daily to the concomitant administration of 0.2% brimonidine ophthalmic solution twice daily and 0.5% timolol ophthalmic solution twice daily. Randomized, multicenter, observer-masked, pa...
Gespeichert in:
Veröffentlicht in: | Ophthalmology (Rochester, Minn.) Minn.), 2003-03, Vol.110 (3), p.615-624 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | To compare the efficacy and tolerability of the 2% dorzolamide/0.5% timolol combination ophthalmic solution twice daily to the concomitant administration of 0.2% brimonidine ophthalmic solution twice daily and 0.5% timolol ophthalmic solution twice daily.
Randomized, multicenter, observer-masked, parallel-group study.
Two hundred ninety-three patients with ocular hypertension or primary open-angle glaucoma participated.
After an open-label 3-week 0.5% timolol run-in period, patients with an hour 2 intraocular pressure (IOP) of ≥ 22 mmHg were randomly assigned to receive either the dorzolamide/timolol combination twice daily or the concomitant use of brimonidine twice daily and timolol twice daily (brimonidine + timolol) for 6 months.
The IOP-lowering effects at hour 0 and hour 2 were collected at 1, 3, and 6 months. We hypothesized that both treatment regimens would have comparable hour 2 IOP-lowering effects at month 3. The treatments were considered comparable if the two-sided 95% confidence interval of the treatment difference was within ± 1.5 mmHg. Tolerability data were also collected at 1, 3, and 6 months.
The primary efficacy analysis was based on the modified intent-to-treat population. At month 3, hour 2, the dorzolamide/timolol group had an adjusted mean (standard error) change in IOP of −5.04 (0.30) mmHg versus −5.41 (0.30) mmHg in the brimonidine + timolol group, with a treatment difference of 0.36 (0.40) mmHg (95% confidence interval [CI] of −0.42–1.14 mmHg). At month 3, hour 0, the dorzolamide/timolol group had a change in IOP of −3.66 (0.29) mmHg versus −4.15 (0.28) mmHg in the brimonidine + timolol group, with a treatment difference of 0.49 (0.39) mmHg (95% CI of −0.27–1.25 mmHg). Likewise, at all other observed time points, the 95% confidence interval of the treatment difference was within ± 1.5 mmHg. Ninety-three patients (64%) in the dorzolamide/timolol group and 88 patients (60%) in the brimonidine + timolol group had adverse experiences that were deemed drug related by the investigator, for which 7 patients (5%) in the dorzolamide/timolol group and 8 patients (5%) in the brimonidine + timolol group were discontinued from the study.
The efficacy of the dorzolamide/timolol combination and the concomitant administration of brimonidine and timolol were comparable. The incidence of drug-related adverse experiences and the incidence of discontinuations caused by drug-related adverse experiences were similar between groups. |
---|---|
ISSN: | 0161-6420 1549-4713 |
DOI: | 10.1016/S0161-6420(02)01900-0 |